Monoclonal Antibodies

Anti-Human RANTES (CCL5) (Monoclonal Mouse)

Product Details

Catalogue Number: 500-M75

Source: Monoclonal Mouse

Preparation: Produced in BALB/c mice immunized with highly pure Recombinant Human RANTES (CCL5). Anti-Human RANTES (CCL5)-specific antibody was purified from ascites fluid by Protein A affinity chromatography.

Immunogen: E.coli derived Recombinant Human RANTES (CCL5) (PeproTech catalog# 300-06)

Sandwich ELISA: In a sandwich ELISA (assuming 100μl/well), a concentration of 2.0-4.0 μg/ml of this antibody will detect at least 500pg/ml of Recombinant Human RANTES when used with PeproTech’s Biotinylated Antigen Affinity Purified anti-Human RANTES (CCL5) (500-P36BT) as the detection antibody at a concentration of approximately 0.5-1.0 μg/ml.

Anti-Human RANTES (CCL5) Sandwich ELISA

Western Blot: To detect Human RANTES by Western Blot analysis this antibody can be used at a concentration of 0.5-1.0 μg/ml. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human RANTES is 0.25-2.0 ng/lane, under reducing conditions and 0.25-0.5 ng/lane, under non-reducing conditions.

Anti-Human RANTES (CCL5) Western Blot Unreduced Anti-Human RANTES (CCL5) Western Blot Reduced

Note:

Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information.

crossreactivity:
Country Of Origin: USA

Not for human use.

Research Interest

product.subtitle.recentcitations

First Author
Xia, M Q
Title
Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains.
Citation
The American Journal of Pathology; 153(1) pg31-7
PubMed Id
First Author
Soria, G
Title
Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.
Citation
BMC Cancer; 11 pg130
PubMed Id
First Author
Yaal-Hahoshen, N
Title
The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research; 12(15) pg4474-80
PubMed Id